ADIL Adial Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-09 16:00
Why ADIL matters now
Adial Pharmaceuticals, Inc. (ADIL) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.80 with -2.38% on the session and $2.7M in market capitalization; recent performance reads 1-month +26.21% and YTD -52.73%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.0M, and EPS of $-1.48. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -261.3%.
The latest indexable market news headline is "Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.00; recent insider activity includes Young Wendy B. filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.96
P/S
0.00
EV/EBITDA
0.27
DCF Value
$7.97
FCF Yield
-261.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-162.8%
ROA
-148.7%
ROIC
-202.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.0M | $-1.48 |
| Q4 2025 | $0.00 | $-2.0M | $-1.80 |
| FY 2025 | $0.00 | $-8.0M | $-11.93 |
| Q3 2025 | $0.00 | $-1.8M | $-2.00 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$6.00 - $8.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.47
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.